Brief: Aequus expects to report topline results from multi-dose study in Q1
14/02/2017 13:00
Feb 14 (Reuters) - Aequus Pharmaceuticals Inc AQS.V :
* Aequus successfully completes dosing in second proof of
concept clinical trial of transdermal aripiprazole patch
* Aequus Pharmaceuticals Inc- company expects to report
topline results from multi-dose study in Q1 of 2017 for AQS1301
Source text for Eikon: ID:nCCN2zJXkW
Further company coverage: AQS.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Aequus Pharmaceuticals
See all newsBrief: Aequus Pharmaceutical Canada Pauses Sales Of Evolve Intensive Eyedrops, Gel In Canada
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange